Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.
Source: Dale Gillham, HotCopper & The Market Online
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Donald Trump’s recent election win has sent Bitcoin soaring past $75,000, marking a dramatic shift in political and market sentiment.

Trump’s pro-Bitcoin stance—an exciting contrast to the previous administration’s cautious approach—has fuelled optimism across the crypto landscape. Many now see this as a pivotal moment for crypto growth, regulatory reform, and renewed investor confidence in digital assets.

With Bitcoin at record highs and momentum building, one question looms large: Is this the perfect moment to hop on Bitcoin’s ride to $100,000?

A more favourable environment for this currency?

Throughout his campaign, Trump actively championed Bitcoin, even proposing a ‘Bitcoin reserve’ to position the US as a global leader in crypto. His commitment to replace SEC Chair Gary Gensler, often seen as a regulatory hurdle, signals a potentially more favourable environment for crypto innovation. This shift could attract traditional investors, allowing more capital to flow into digital assets with fewer barriers. Trump’s focus on strengthening US-based Bitcoin mining also hints at enhanced network stability and reduced dependence on foreign mining hubs.

Analysts see this Bitcoin rally as possibly just the beginning, with some forecasting it could breach $100,000. After consolidating and dipping to $49,202 in August, Bitcoin has since resumed its upward trend, breaking through prior consolidation highs and setting a new all-time high this week. Bitcoin’s next major test will likely be the $80,000 resistance, with a strong breakout above this level potentially pushing it closer to $100,000.

For those interested in crypto exposure without extreme volatility, the CRYP ETF on the ASX offers a diversified entry point. After falling 90 per cent from its IPO listing, the ETF has found support around $1.36 and is trending upward, with the next major resistance around $7. A break above this level could see a rise back up to the all-time high of around $12.

What are the best and worst-performing sectors this week?

The best-performing sectors include Information Technology, up four per cent, followed by Industrials, up over three per cent and Financials, up over two per cent. The worst-performing sectors include Real Estate, down over two per cent, followed by Materials and Consumer Staples, both down under half a per cent.

The best-performing stocks in the ASX top 100 include Bluescope Steel and Computershare, both up over 11 per cent, followed by Worley Limited, up over nine per cent. The worst-performing stocks include A2 Milk, down over nine per cent, followed by Evolution Mining and Northern Star, both down over six per cent.

What’s next for the Australian stock market?

This week, buyers returned with renewed energy, pushing the All Ordinaries Index up by over one per cent—a clear signal that the bull market remains strong. Reinforcing this trend, buyers have consistently stepped in since November 2023, limiting selling pressure to no more than two consecutive weeks before the market turns to trade back up.

While this election was primed to trigger wild price swings in price, we didn’t experience this. Instead, the S&P 500 surged by over two and a half per cent in a single day following the election, while the Australian market remained relatively steady. While the upside movement was modest, the positive takeaway is the lack of significant downside volatility, underscoring market confidence in the current uptrend.

The mining sector, in particular, has seen renewed buying interest. Following Donald Trump’s post-election remarks on continuing support for fossil fuels—referring to them as ‘liquid gold’—confidence in this sector has been reignited. This endorsement is welcome news for some of Australia’s largest miners, including BHP, Rio Tinto, South32, and Oz Minerals, all of which have a substantial US presence. This boost in sentiment provides the assurance these companies need to propel growth in the sector.

Moving forward, I expect the All Ordinaries Index to test the current all-time high of 8,654 points. If sellers reassert themselves and push the index below last week’s low of 8,323, it will be necessary to reassess the short-term direction over the coming weeks. Regardless of any short-term movement, with election uncertainties behind us and buyer momentum rising, now is the perfect time to take action and implement your investment plans.

For now, good luck and good trading.

Dale Gillham is the Chief Analyst at Wealth Within and the international bestselling author of How to Beat the Managed Funds by 20%. He is also the author of the bestselling and award-winning book Accelerate Your Wealth—It’s Your Money, Your Choice, which is available in all good bookstores and online at www.wealthwithin.com.au

Disclaimer: While Wealth Within holds an Australian Financial Services License (AFSL:226347) the information featured in this program is general in nature and therefore should not be relied upon.

Before making any investment decisions, you should consult a licensed professional who can advise whether your investment decisions are appropriate for you.

More From The Market Online
Donald Trump supporter photographed in lead up to 2024 election

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

The Dow Jones finished up +3% on election day; the NASDAQ and S&P weren’t far behind.…
The Market Online Video

ASX Market Close: IT stocks lead bourse higher | November 8, 2024

The market remains buoyant in the wake of Trump’s election in the United States, and the…
Golden sun across a mountain ridge

Flynn Gold reaches milestone exploration target for Golden Ridge

Flynn Gold Ltd has achieved a maiden exploration target for the Trafalgar, Brilliant and Link Zone…
Image of t-cells

Imugene kicks off Australian trial for blood cancer treatment

Imugene Ltd has opened its first Australian trial for a Phase 1b clinical trial to test…